Support Our Work

Please donate so we can continue our work to reduce the stigma of psychiatric illness, encourage research, and support educational activities for behavioral health professionals and the public. Ways you can donate and help are on our Support and Donations page. Thank you!

More Info

Latest News Around the Web

Study Reveals “Psychiatric Boarding Crisis” In The US During COVID-19 Pandemic

Healio (7/7, Weldon) reported, “There was a ‘psychiatric boarding crisis’ in the United States during the COVID-19 pandemic, as psychiatric services were not prepared to support the number of youths needing care,” investigators concluded after cataloging “7,625 psychiatric emergency services encounters of patients aged four to 20 years who attended one of five mobile clinics operated by the Boston Emergency Services Team in Massachusetts.” The study suggested that “pediatric mental health services were not prepared for the number of youths needing care during the COVID-19 pandemic,” with “a lack of beds and staff” possibly having “contributed to the hardship.” The findings were published online July 6 in JAMA Network Open.

Related Links:

— “US had ‘psychiatric boarding crisis’ during COVID-19 pandemic,”Rose Weldon, Healio, July 7, 2023

Americans Engaging In Creative Activities Report Better Mental Health, APA Poll Finds

HealthDay (7/7, Murez) reported, “Americans who engage in creative activities – from crafting to playing the piano to painting — report better mental health, according to” findings from a 2,202-adult Healthy Minds Monthly Poll conducted in June by the American Psychiatric Association and announced in a July 6 news release. In that release, APA President Petros Levounis, MD, MA, stated, “Creative activities aren’t just for fun, they can help us take a step back from the daily grind, use our brains differently, and relax,” and “picking up that paintbrush or solving a tricky puzzle can truly move us to a different mindset.” APA CEO and Medical Director Saul Levin, MD, MPA, said, “APA is pleased to call attention to these positive actions as part of the public discussion on mental health.”

Related Links:

— “Expressing Yourself Creatively Gives Mental Health Boost, Poll Finds,”Cara Murez, HealthDay, July 7, 2023

Substance Use Disorders, Fatal Overdoses Among US Seniors Have Climbed Steeply, Studies Indicate

According to the New York Times (7/9, Span), “as baby boomers have turned 65, the age at which they typically qualify for Medicare, substance use disorders among the older population have climbed steeply.” For instance, “a study of opioid use disorder in people over 65 enrolled in traditional Medicare” published in a research brief in the June 2021 issue of the American Journal of Preventive Medicine, “showed a threefold increase in just five years – to 15.7 cases per 1,000 in 2018 from 4.6 cases per 1,000 in 2013.” Additionally, “fatal overdoses have…soared among seniors,” according to the findings of a research letter published online March 29 in JAMA Psychiatry.

Related Links:

— “Substance Abuse Is Climbing Among Seniors,”Paula Span, The New York Times, July 9, 2023

FDA Approves Lecanemab for Treatment of patients with Alzheimer’s

The New York Times (7/6, Belluck) reports the FDA granted “full approval to the Alzheimer’s drug Leqembi (lecanemab), and Medicare said it would cover much of its high cost, laying the foundation for widespread use of a medication that can modestly slow cognitive decline in the early stages of the disease but also carries significant safety risks.” The agency’s “decision marks the first time in two decades that a drug for Alzheimer’s has received full approval, meaning that the agency concluded there is solid evidence of potential benefit.” However, the FDA “also added a so-called black-box warning…stating that in rare cases the drug can cause ‘serious and life-threatening events.’”

Reuters (7/6, Beasley, Steenhuysen) reports the drug, “which is given intravenously, has a U.S. list price of $26,500 per year.” The “new label explains the need to monitor patients for potentially dangerous brain swelling and bleeding associated with amyloid-lowering antibodies.” Additionally, “the drug’s new label includes data showing that the use of certain anti-coagulants with Leqembi has been linked to a risk of brain hemorrhage.”

Related Links:

— “New Federal Decisions Make Alzheimer’s Drug Leqembi Widely Accessible,”Pam Belluck, The New York Times , July 6, 2023

Cannabis Use Disorder Tied To Higher Risk Of Morbidity, Mortality After Major Elective Surgery, Research Finds

MedPage Today (7/6, Putka) reports, “Adults with cannabis use disorder had a moderately increased risk of morbidity and in-hospital mortality after major elective surgery compared with those without cannabis use disorder, a large retrospective study found.” Data show that “among 12,422 hospitalized patients, a composite outcome of perioperative complications and mortality occurred in 7.73% of the cannabis use disorder group and 6.57% of a matched control group.” The findings were published online in JAMA Surgery.

Related Links:

MedPage Today (requires login and subscription)

Foundation News

Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.